Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 27.993
Citescore: 28.5
All metrics >>

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Current Issue

Key Articles from the last 75 years

Commentaries on key papers from 1947

Tore Kvien highlights the importance of 4 key papers published in the journal in 1947, the year that EULAR was founded.

Commentaries on key papers from 1972

Johannes Bijlsma presents 5 key papers published in the journal 50 years ago.

Celebrating 75 Years of EULAR

Highlights from EULAR to celebrate their 75th anniversary.

EULAR 2022 Congress Abstracts

Access the 2022 EULAR Congress abstracts for free online.

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Editor's Choice

Education:

Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countries

12 September 2022

Spondyloarthritis:

MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group

11 August 2022

Epidemiology:

2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases

12 July 2022

Paediatric rheumatology:

Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases

10 June 2022

Latest Articles

Rheumatoid arthritis:

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

23 September 2022

Crystal arthropathies:

Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment

23 September 2022

Rheumatoid arthritis:

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis

23 September 2022

Reviews:

From real-world electronic health record data to real-world results using artificial intelligence

23 September 2022

Rheumatoid arthritis:

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

22 September 2022

Articles by Topic

View full list

Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

All EULAR recommendations are free to access.

Each recommendation also has an accompanying lay summary, which is also free to access.

Video

ROSAH syndrome is an autoinflammatory disease

11 August 2022

ROSAH syndrome is an autoinflammatory disease caused by gain-of-function mutations in ALPK1 and some features of disease are amenable to immunomodulatory therapy.

Find out more